Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The primary hypotheses are: Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS) pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab …

paclitaxel
non-small cell lung cancer
immunomodulators
stage iii non-small cell lung cancer
lung neoplasm
  • 0 views
  • 19 Feb, 2024
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free …

squamous cell carcinoma
external beam radiation therapy
concurrent radiochemotherapy
adenosquamous carcinoma
excisional biopsy
  • 0 views
  • 19 Feb, 2024
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Endometrial Cancer

A multicenter, prospective, randomized controlled study to compare the "sanwich" mode of radiochemotherapy and the "concurrent chemoradiotherapy followed by chemotherapy" mode will be carried out to determine the better modality of radiochemotherapy in stage III endometrial adenocarcinoma.

chemoradiotherapy
endometrial cancer
adjuvant radiotherapy
adjuvant
platelet count
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy followed by concurrent chemoradiation for previously untreated locoregionally advanced stage III to IVA NPC.

intra articular injection
bilateral oophorectomy
immunomodulators
topical steroids
oophorectomy
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve the survival rate of high-risk patients and may provide new evidence for individualized comprehensive treatment of …

chemoradiotherapy
induction chemotherapy
EGFR
epstein-barr virus dna
concurrent radiochemotherapy
  • 4 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and efficacy.

primary lesion
squamous cell carcinoma
mucous membrane
lymph node metastases
esophageal carcinoma
  • 0 views
  • 19 Feb, 2024
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

paclitaxel
chemoradiotherapy
esophageal cancer
measurable disease
monoclonal antibodies
  • 0 views
  • 19 Feb, 2024
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma

A Phase II trial to study the effectiveness and security of cisplatin concurrent chemoradiotherapy plus TIL versus cisplatin concurrent chemoradiotherapy only in treating patients with FIGO stage IIIA to IVA cervical carcinoma.

concomitant radiochemotherapy
chemoradiotherapy
cervical cancer
squamous cell carcinoma
adenosquamous carcinoma
  • 0 views
  • 19 Feb, 2024
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.

paclitaxel
chemoradiotherapy
cervical cancer
squamous cell carcinoma
adenosquamous carcinoma
  • 0 views
  • 19 Feb, 2024
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

chemoradiotherapy
metastasis
induction chemotherapy
docetaxel
concurrent radiochemotherapy
  • 0 views
  • 19 Feb, 2024